Phosphoinositide 3-kinase-gamma as a target in rheumatoid arthritis and systemic lupus.
Doggrell
Sheila A
SA
Charles Darwin University, School of Science, Casuarina, NT 0811, Australia. sheila.doggrell@cdu.edu.au
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000201:enzymology*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000201:enzymology*; D051379:Mice; D015394:Molecular Structure; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011810:Quinoxalines / Q000737:chemistry / Q000627:therapeutic use*; D045162:Thiazolidinediones / Q000737:chemistry / Q000627:therapeutic use*
D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011810:Quinoxalines; D045162:Thiazolidinediones; C505144:5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione